Two case reports on the use of genistein combined polysaccharide (GCP) against bladder cancer recurrence.

Abstract

We followed two subjects with resected stage Ta superficial transitional cell carcinoma (TCC) of the bladder who had not received intravesicle bacillus Calmette-Guerin (BCG) and received supplementation with the agent Genistein Combined Polysaccharide (GCP) in an IRB approved study. The observation period was 12 months for both cases. After the yearly oral dosage of GCP, there was no recurrence in either of the subjects as determined by cytoscopy, urine cytology, and fluorescence in-situ hybridization analysis of urine (UrovysionTM FISH Assay). The intravenous pyelogram (IVP), obtained at baseline and after 12 months, was also negative. There were no adverse events over the course of treatment and had full patient compliance and tolerability of the GCP agent in both cases.

• Authors: Jillian L Capodice, A S Cammack, James M McKiernan, Aaron E Katz
• Journal: Journal of complementary & integrative medicine (J Complement Integr Med) Vol. 8 (Jan 2011) ISSN: 1553-3840 [Electronic] Germany
• PMID: 22754921 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anticarcinogenic Agents
• Polysaccharides
• genistein combined polysaccharide
• Genistein

Topics

• Aged
• Anticarcinogenic Agents (therapeutic use)
• Carcinoma, Transitional Cell (drug therapy)
• Dietary Supplements
• Genistein (therapeutic use)
• Humans
• Male
• Neoplasm Recurrence, Local (prevention & control)
• Polysaccharides (therapeutic use)
• Urinary Bladder Neoplasms (drug therapy)